2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

Cencora raised fiscal 2026 adjusted EPS guidance to $17.70-$17.90 after reporting Q2 revenue of $78.4B, up 3.8% year over year, with adjusted EPS up 7.5% to $4.75. The company is also buying back shares, with $1B planned by end-2026 plus an additional $2B authorization, while margin expansion continues from the OneOncology acquisition. Stevanato posted Q1 revenue of 273.6 million euros, up 7%, with GLP-1 products contributing 21%-22% of revenue and adjusted EBITDA margin expanding 150 bps to 23.9%.

Analysis

COR is the cleaner near-term earnings comp, but the market is still pricing it like a low-growth commodity distributor even as specialty mix and buybacks create a multiple re-rating path. The real second-order effect is that oncology and specialty adjacency reduce cyclicality: once physicians, payors, and dispensing workflows are embedded, switching costs rise and margin expansion can persist longer than headline distribution economics would suggest. That makes COR less about volume growth and more about incremental spread capture plus capital return compounding over the next 4-8 quarters.

STVN is the higher-beta way to express the same healthcare defensiveness with a more asymmetric operating lever. The market is likely underestimating the lag between GLP-1 demand and manufacturing footprint completion: once capacity upgrades are absorbed, operating leverage should show up with a delay, not all at once, which can support several quarters of estimate revisions. The key nuance is that STVN’s revenue concentration is a feature, not a bug, if the concentration is tied to a secular injectable platform where packaging and delivery infrastructure are harder to displace than the branded drugs themselves.

The consensus is likely missing that both names are beneficiaries of a broader “picks and shovels” trade in healthcare, but STVN has more valuation sensitivity to any evidence that GLP-1 demand is durable beyond the current obesity cycle. If adoption normalizes or payor scrutiny intensifies, STVN’s multiple can compress quickly because the market is paying for visible growth, not just quality. COR has less downside from demand normalization, but more upside is capped unless management keeps converting acquisitions into margin accretion.

Over the next 1-3 months, watch for guidance raises and buyback execution as the main catalysts. Over 6-12 months, the setup favors names where margin expansion is still underappreciated and where balance-sheet repair turns into faster EPS growth than the market is modeling.

Key Decisions for Investors

• Long COR on a 6-12 month horizon into any post-earnings weakness: favor a 1-2x position size versus broad healthcare because buybacks plus specialty mix should support low-double-digit EPS comp even without multiple expansion.
• Long STVN as the higher-upside expression of GLP-1 infrastructure on a 6-9 month horizon; target add-on entries on pullbacks because the stock is more sensitive to estimate revisions than to near-term macro noise.
• Pair trade: long STVN / short a basket of large-cap healthcare distribution or device names with less growth torque if you want exposure to secular injectable demand with less market beta; thesis breaks if GLP-1 volumes decelerate materially.
• Use COR as a lower-volatility hedge against a broader healthcare drawdown: if sentiment deteriorates, the company’s capital return and defensive cash generation should preserve relative performance better than higher-multiple healthcare peers.
• Avoid chasing after a sharp rerating in either name; the cleaner setup is to buy on confirmation of another guidance raise or visible buyback acceleration rather than front-running the entire revaluation.